A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

计划入组 272 人 · 首次发布于 2024 年 3 月 12 日

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

计划入组 160 人 · 首次发布于 2025 年 5 月 7 日

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

计划入组 1,089 人 · 首次发布于 2023 年 7 月 6 日

mRNA-4157

B-4157

Troriluzole

C₁₅H₁₆F₃N₅O₄S

Moderna, Inc.

United States

BioNTech SE

Germany

Eterna Therapeutics

United States

Merck and Moderna Launch Phase 3 Trial of V940 (mRNA-4157) Plus KEYTRUDA in NSCLC

Merck and Moderna Launch Phase 3 Trial of V940 (mRNA-4157) with Keytruda in NSCLC

Merck and Moderna Launch Phase 3 Trial of V940/Keytruda Adjuvant Therapy for NSCLC